Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity

Nature Communications

Volumn 5, Issue , 2014, Pages

  Adhireksan, Zenita ^a   Davey, Gabriela E ^a   Campomanes, Pablo ^b,c   Groessl, Michael ^d   Clavel, Catherine M ^b   Yu, Haojie ^a   Nazarov, Alexey A ^b,f   Yeo, Charmian Hui Fang ^e   Ang, Wee Han ^e   Dröge, Peter ^a   Rothlisberger, Ursula ^b   Dyson, Paul J ^b   Davey, Curt A ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b EPFL   (Switzerland)

^c Computational Biophysics German Research School for Simulation Sciences ^*  (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; RUTHENIUM COMPLEX;

CANCER; DNA; DRUG; LIGAND; PROTEIN; RUTHENIUM; TOXICITY; TUMOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CHROMATIN; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG STRUCTURE; EPIGENETICS; GENE TARGETING; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN TARGETING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA; HUMANS; KINETICS; LIGANDS; MOLECULAR STRUCTURE; MONOTERPENES; PROTEIN BINDING; PROTEINS; RUTHENIUM;

EID: 84897031169     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4462     Document Type: Article

References (61)

1. Jung, Y. & Lippard, S. J. Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107, 1387-1407 (2007).
2. Todd, R. C. & Lippard, S. J. Inhibition of transcription by platinum antitumor compounds. Metallomics 1, 280-291 (2009).
3. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584 (2007).
4. Wu, B., Davey, G. E., Nazarov, A. A., Dyson, P. J. & Davey, C. A. Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation. Nucleic Acids Res. 39, 8200-8212 (2011).
5. Sava, G., Bergamo, A. & Dyson, P. J. Metal-based antitumour drugs in the postgenomic era: what comes next? Dalton Trans. 40, 9069-9075 (2011).
6. Ang, W. H., Casini, A., Sava, G. & Dyson, P. J. Organometallic rutheniumbased antitumor compounds with novel modes of action. J. Organometallic Chem. 696, 989-998 (2011).
7. Heffeter, P. et al. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J. Biol. Inorg. Chem. 15, 737-748 (2010).
8. Wu, B. et al. A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. Chemistry 17, 3562-3566 (2011).
9. Groessl, M., Zava, O. & Dyson, P. J. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. Metallomics 3, 591-599 (2011).
10. Wolters, D. A., Stefanopoulou, M., Dyson, P. J. & Groessl, M. Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells. Metallomics 4, 1185-1196 (2012).
11. Davey, G. E. & Davey, C. A. Chromatin - a new, old drug target? Chem. Biol. Drug Des. 72, 165-170 (2008).
12. Allardyce, C. S., Dyson, P. J., Ellis, D. J. & Heath, S. L. [Ru(eta(6)-p-cymene)Cl- 2(pta)] (pt=1,3,5-triaza-7-phosphatricyclo[3.3.1.1] decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem. Commun. 15, 1396-1397 (2001).
13. Scolaro, C. et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J. Med. Chem. 48, 4161-4171 (2005).
14. Nowak-Sliwinska, P. et al. Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J. Med. Chem. 54, 3895-3902 (2011).
15. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813-823 (2006).
16. Morris, R. E. et al. Inhibition of cancer cell growth by ruthenium(II) arene complexes. J. Med. Chem. 44, 3616-3621 (2001).
17. Aird, R. E. et al. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br. J. Cancer 86, 1652-1657 (2002).
18. Galea, A. M. & Murray, V. The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim. Biophys. Acta 1579, 142-152 (2002).
19. Novakova, O. et al. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. Biochemistry 42, 11544-11554 (2003).
20. Novakova, O. et al. Conformation of DNA modified by monofunctional Ru(II) arene complexes: recognition by DNA binding proteins and repair. Relationship to cytotoxicity. Chem. Biol. 12, 121-129 (2005).
21. Wu, B., Droge, P. & Davey, C. A. Site selectivity of platinum anticancer therapeutics. Nat. Chem. Biol. 4, 110-112 (2008).
22. Davey, G. E., Wu, B., Dong, Y., Surana, U. & Davey, C. A. DNA stretching in the nucleosome facilitates alkylation by an intercalating antitumour agent. Nucleic Acids Res. 38, 2081-2088 (2010).
23. Ong, M. S., Richmond, T. J. & Davey, C. A. DNA stretching and extreme kinking in the nucleosome core. J. Mol. Biol. 368, 1067-1074 (2007).
24. Tan, S. & Davey, C. A. Nucleosome structural studies. Curr. Opin. Struct. Biol. 21, 128-136 (2011).
25. Chua, E. Y., Vasudevan, D., Davey, G. E., Wu, B. & Davey, C. A. The mechanics behind DNA sequence-dependent properties of the nucleosome. Nucleic Acids Res. 40, 6338-6352 (2012).
26. Scolaro, C., Hartinger, C. G., Allardyce, C. S., Keppler, B. K. & Dyson, P. J. Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(Z6-p-cymene)Cl2(pta)]. J. Inorg. Biochem. 102, 1743-1748 (2008).
27. Mahalanobis, P. C. On the generalised distance in statistics. Proc. Natl Inst. Sci. India 2, 49-55 (1936).
28. Behrens, B. C. et al. Characterization of a cis- diamminedichloroplatinum(II)- resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47, 414-418 (1987).
29. Weigelt, B., Peterse, J. L. & van 't Veer, L. J. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591-602 (2005).
30. Mehlen, P. & Puisieux, A. Metastasis: a question of life or death. Nat. Rev. Cancer 6, 449-458 (2006).
31. Rodriguez-Paredes, M. & Esteller, M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17, 330-339 (2011).
32. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11, 726-734 (2011).
33. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
34. Tran, M. Q., Nygren, Y., Lundin, C., Naredi, P. & Bjorn, E. Evaluation of cell lysis methods for platinum metallomic studies of human malignant cells. Anal. Biochem. 396, 76-82 (2010).
35. Soltes, L. The Hummel-Dreyer method: impact in pharmacology. Biomed. Chromatogr. 18, 259-271 (2004).
36. Maxam, A. M. & Gilbert, W. Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol. 65, 499-560 (1980).
37. Davey, C. A., Sargent, D. F., Luger, K., Maeder, A. W. & Richmond, T. J. Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 A resolution. J. Mol. Biol. 319, 1097-1113 (2002).
38. Leslie, A. G. The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62, 48-57 (2006).
39. Bailey, S. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
40. Hornak, V. et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65, 712-725 (2006).
41. Perez, A. et al. Refinement of the AMBER force field for nucleic acids: Improving the description of alpha/gamma conformers. Biophys. J. 92, 3817-3829 (2007).
42. Banas, P. et al. Performance of molecular mechanics force fields for RNA simulations: Stability of UUCG and GNRA hairpins. J. Chem. Theory Comput. 6, 3836-3849 (2010).
43. Joung, S. & Cheatham, III. T. E. Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. J. Phys. Chem. B 112, 9020-9041 (2008).
44. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935 (1983).
45. Gossens, C., Tavernelli, I. & Rothlisberger, U. DNA structural distorsions induced by ruthenium-arene anticancer compounds. J. Am. Chem. Soc. 130, 10921-10928 (2008).
46. Essmann, U. et al. A smooth particle mesh Ewald method. J. Chem. Phys. 103, 8577-8593 (1995).
47. Kale, L. et al. NAMD2: greater scalability for parallel molecular dynamics. J. Comput. Phys. 151, 283-312 (1999).
48. VandeVondele, J. et al. QUICKSTEP: Fast and accurate density functional calculations using a mixed Gaussian and plane waves approach. Comput. Phys. Commun. 167, 103-128 (2005).
49. Laino, T., Mohamed, F., Laio, A. & Parrinello, M. An efficient real space multigrid QM/MM electrostatic coupling. J. Chem. Theory Comput. 1, 1176-1184 (2005).
50. Laio, A., VandeVondele, J. & Rothlisberger, U. A Hamiltonian electrostatic coupling scheme for hybrid Car-Parrinello molecular dynamics simulations. J. Chem. Phys. 116, 6941-6948 (2002).
51. VandeVondele, J. & Hutter, J. Gaussian basis sets for accurate calculations on molecular systems in gas and condensed phases. J. Chem. Phys. 127, 114105 (2007).
52. Goedecker, S., Teter, M. & Hutter, J. Separable dual-space Gaussian pseudopotentials. Phys. Rev. B 54, 1703-1710 (1996).
53. Hartwigsen, C., Goedecker, S. & Hutter, J. Relativistic separable dual-space Gaussian pseudopotentials from H to Rn. Phys. Rev. B 58, 3641-3662 (1998).
54. Perdew, J. P., Burke, K. & Ernzerhof, M. Generalized gradient approximation made simple. Phys. Rev. Lett. 77, 3865-3868 (1996).
55. Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocityrescaling. J. Chem. Phys. 126, 014101 (2007).
56. Sprik, M. & Ciccotti, G. Free energy from constrained molecular dynamics. J. Chem. Phys. 109, 7737-7744 (1998).
57. Frisch, M. J. et al. Gaussian 09, Revision B.01. Gaussian, Inc. (2009).
58. Becke, A. D. Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys. 98, 5648-5652 (1993).
59. Hay, P. J. & Wadt, W. R. Ab initio effective core potentials for molecular calculations. Potentials for K to Au including the outermost core orbitals. J. Chem. Phys. 82, 299-310 (1985).
60. Tomasi, J., Mennucci, B. & Cammi, R. Quantum mechanical continuum solvation models. Chem. Rev. 105, 2999-3093 (2005).
61. Barone, V., Cossi, M. & Tomasi, J. A new definition of cavities for the computation of solvation free energies by the polarizable continuum model. J. Chem. Phys. 107, 3210-3221 (1997).